Pharmacogenetics in drug discovery and development: a translational perspective
暂无分享,去创建一个
[1] Steven Gallinger,et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 , 2007, Nature Genetics.
[3] Rebecca F. Halperin,et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. , 2007, The Journal of clinical psychiatry.
[4] H. Stefánsson,et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.
[5] K. Johnson. An Update. , 1984, Journal of food protection.
[6] P. Whitehouse,et al. Genetic Testing for Alzheimer Disease-Reply , 1997 .
[7] Hakon Hakonarson,et al. Recent development in pharmacogenomics: from candidate genes to genome-wide association studies , 2007, Expert review of molecular diagnostics.
[8] Tae Won Kim,et al. Insights, Challenges, and Future Directions in Irinogenetics , 2007, Therapeutic drug monitoring.
[9] C. DeCarli,et al. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study , 2007, BMC Medical Genetics.
[10] L J Lesko,et al. Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.
[11] J. Drazen,et al. Rosiglitazone--continued uncertainty about safety. , 2007, The New England journal of medicine.
[12] J. Stern,et al. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. , 2001, The AIDS reader.
[13] L. Hogarth,et al. The thiopurines: An update , 2005, Investigational New Drugs.
[14] Zhaohui S. Qin,et al. A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.
[15] J. Hirschhorn,et al. A comprehensive review of genetic association studies , 2002, Genetics in Medicine.
[16] Toshihiro Tanaka. The International HapMap Project , 2003, Nature.
[17] T. Hudson,et al. A genome-wide association study identifies novel risk loci for type 2 diabetes , 2007, Nature.
[18] A. Kibel. Multiple newly identified loci associated with prostate cancer susceptibility , 2009 .
[19] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[20] P. Goss,et al. Lapatinib-associated toxicity and practical management recommendations. , 2007, The oncologist.
[21] D. Haber,et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. , 2005, Cold Spring Harbor symposia on quantitative biology.
[22] W. Willett,et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.
[23] D. Galas,et al. A new five-year plan for the U.S. Human Genome Project. , 1993, Science.
[24] A. Roses,et al. Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. , 1993, Stroke.
[25] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[26] R. Mahley,et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] W. Willett,et al. Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.
[28] A. Chow,et al. Case report and literature review , 1981 .
[29] Richard Pazdur,et al. End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Sonja W. Scholz,et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data , 2007, The Lancet Neurology.
[31] David B. Goldstein,et al. Pharmacogenetics goes genomic , 2003, Nature Reviews Genetics.
[32] G. D. Dal Pan,et al. Estimating the extent of reporting to FDA: a case study of statin‐associated rhabdomyolysis , 2008, Pharmacoepidemiology and drug safety.
[33] U. Heine,et al. HLA-B*5701 clinical testing: early experience in the United States , 2007, Pharmacogenetics and genomics.
[34] M. Pericak-Vance,et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. , 1991, American journal of human genetics.
[35] J. Haines,et al. Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study. , 2003, American heart journal.
[36] David Walker,et al. Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus , 2006, The Journal of Neuroscience.
[37] F. Paccaud,et al. High prevalence of major cardiovascular risk factors in first-degree relatives of individuals with familial premature coronary artery disease--the GENECARD project. , 2007, Atherosclerosis.
[38] I. Vizirianakis. Clinical Translation of Genotyping and Haplotyping Data , 2007, Clinical pharmacokinetics.
[39] K. Taylor,et al. Genome-Wide Association , 2007, Diabetes.
[40] D. Curtis,et al. Further Investigation of Linkage Disequilibrium SNPs and their Ability to Identify Associated Susceptibility Loci , 2004, Annals of Human Genetics.
[41] A. Holden. The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events. , 2007, Drug discovery today. Technologies.
[42] Use of whole-genome association scans in disease gene identification, drug discovery and development. , 2007, IDrugs : the investigational drugs journal.
[43] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[44] M. McCarthy,et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.
[45] Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector? , 2008, British journal of clinical pharmacology.
[46] R. Mahley,et al. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[47] Jordan W. Smoller,et al. Genetics of bipolar disorder , 2007, Current psychiatry reports.
[48] A. Holden,et al. The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. , 2002, BioTechniques.
[49] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[50] A D Roses,et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.
[51] Muin J. Khoury,et al. Genetic Association Studies of Cancer: Where Do We Go from Here? , 2007, Cancer Epidemiology Biomarkers & Prevention.
[52] H. Tilson,et al. The US drug safety system: role of the pharmaceutical industry , 2008, Pharmacoepidemiology and drug safety.
[53] L. Ferguson,et al. Nutrigenomics in the whole-genome scanning era: Crohn’s disease as example , 2007, Cellular and Molecular Life Sciences.
[54] Simon Heath,et al. Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4 , 2007, PLoS genetics.
[55] Scott F. Saccone,et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. , 2007, Human molecular genetics.
[56] L. Lesko,et al. Personalized Medicine: Elusive Dream or Imminent Reality? , 2007, Clinical pharmacology and therapeutics.
[57] J. Gulcher,et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution , 2007, Nature Genetics.
[58] Denys T. Lau,et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. , 2007, Archives of internal medicine.
[59] Alexander T Florence,et al. Nanoparticle uptake by the oral route: Fulfilling its potential? , 2005, Drug discovery today. Technologies.
[60] G. Abecasis,et al. A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility Variants , 2007, Science.
[61] G. Abecasis,et al. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. , 2007, Human molecular genetics.
[62] Simon C. Potter,et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.
[63] M. Reger,et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[64] E Lai,et al. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. , 1998, Genomics.
[65] Miles Parkes,et al. Genome‐wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: Lessons for study design , 2007, Inflammatory bowel diseases.
[66] A. Roses. Pharmacogenetics and the practice of medicine , 2000, Nature.
[67] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[68] A D Roses,et al. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. , 2000, Biochimica et biophysica acta.
[69] H. Friess,et al. Molecular pathogenesis of pancreatic cancer: advances and challenges. , 2007, Current molecular medicine.
[70] E. Silverman. Genetics of chronic obstructive pulmonary disease. , 2008, Novartis Foundation symposium.
[71] Shazib Pervaiz,et al. Druggability of human disease genes. , 2007, The international journal of biochemistry & cell biology.
[72] Lefkos Middleton,et al. Disease-specific target selection: a critical first step down the right road. , 2005, Drug discovery today.
[73] John P.A. Ioannidis,et al. Non-Replication and Inconsistency in the Genome-Wide Association Setting , 2007, Human Heredity.
[74] J. Lilleyman,et al. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. , 1996, Therapeutic drug monitoring.
[75] A. Roses,et al. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects , 2005, Pharmacogenetics and genomics.
[76] A. Roses,et al. “Personalized Medicine: Elusive Dream or Imminent Reality?”: A Commentary , 2007, Clinical pharmacology and therapeutics.
[77] M. Relling,et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[79] Lincoln Stein,et al. The SNP Consortium website: past, present and future , 2003, Nucleic Acids Res..
[80] P. S. St George-Hyslop,et al. Association between SORL1 and Alzheimer's disease in a genome-wide study , 2007, Neuroreport.
[81] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[82] J. Gilbert,et al. Cis-Acting Human ApoE Tissue Expression Element is Associated with Human Pattern of Intraneuronal ApoE in Transgenic Mice , 1998, Neurobiology of Aging.
[83] S. Mallal,et al. Pharmacogenetics and the potential for the individualization of antiretroviral therapy , 2008, Current opinion in infectious diseases.
[84] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[85] R. Mahley,et al. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[86] D. Curtis,et al. A pragmatic suggestion for dealing with results for candidate genes obtained from genome wide association studies , 2007, BMC Genetics.
[87] T. Frayling. Genome–wide association studies provide new insights into type 2 diabetes aetiology , 2007, Nature Reviews Genetics.
[88] D. Burns,et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility , 2008, The Pharmacogenomics Journal.
[89] Lawrence A Leiter,et al. Stimulation of Cholecystokinin‐A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients , 2008, Clinical pharmacology and therapeutics.
[90] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.
[91] S. Amur,et al. The Experience with Voluntary Genomic Data Submissions at the FDA and a Vision for the Future of the Voluntary Data Submission Program , 2007, Clinical pharmacology and therapeutics.
[92] Allen D. Roses,et al. Pharmacogenetics and drug development: the path to safer and more effective drugs , 2004, Nature Reviews Genetics.
[93] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[94] M. Shearer,et al. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.
[95] S. Mallal,et al. External Quality Assessment of HLA-B*5701 Reporting: An International Multicentre Survey , 2007, Antiviral therapy.
[96] Jean-Luc Wybo,et al. 11/9: a historical perspective , 2003 .
[97] Leonid Kruglyak,et al. The road to genome-wide association studies , 2008, Nature Reviews Genetics.
[98] M. McCarthy,et al. Genetics of type 2 diabetes. , 2007, Current diabetes reports.
[99] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[100] A. Roses,et al. Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan , 2007, The Pharmacogenomics Journal.
[101] O. Naderer,et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.
[102] A D Roses,et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease) , 2007, The Pharmacogenomics Journal.
[103] J. Witte,et al. Genome-wide association studies of cancer. , 2007, Future oncology.
[104] F. Pasquier,et al. A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Aβ Levels, and Alzheimer's Disease Risk , 2008, Cell.
[105] J. Oldenburg,et al. Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles , 2007, Thrombosis and Haemostasis.
[106] Felix W Frueh,et al. Implementing the U.S. FDA guidance on pharmacogenomic data submissions , 2007, Environmental and molecular mutagenesis.
[107] E. Nimmo,et al. The Genetics of Inflammatory Bowel Disease , 2007, The American Journal of Gastroenterology.
[108] A. Roses. Genome-wide screening for drug discovery and companion diagnostics , 2007, Expert opinion on drug discovery.
[109] Harry Seifert,et al. Database size and power to detect safety signals in pharmacovigilance , 2007, Expert opinion on drug safety.
[110] S. Craft,et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice , 2006, Experimental Neurology.
[111] N. Molfino. Genetic predisposition to accelerated decline of lung function in COPD , 2007, International journal of chronic obstructive pulmonary disease.
[112] F. Paccaud,et al. [Health examination survey of the Lausanne population: first results of the CoLaus study]. , 2006, Revue medicale suisse.
[113] 加藤 俊介. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer , 2009 .
[114] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[115] M. Ehm,et al. Role of pharmacogenetic studies in early clinical development: Phase I studies with lapatinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] Christopher G. Mathew,et al. New links to the pathogenesis of Crohn disease provided by genome-wide association scans , 2008, Nature Reviews Genetics.
[117] D. Germano,et al. Lapatinib in breast cancer. , 2007, Annals of Oncology.
[118] Andreas Fregin,et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.
[119] Clive E. Bowman,et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.
[120] M. Gill,et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. , 2007, Human molecular genetics.
[121] John D Potter,et al. Genetic variation and cancer: improving the environment for publication of association studies. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[122] RA Salerno,et al. Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop , 2006, The Pharmacogenomics Journal.
[123] Lord Baldwin,et al. The Role of the Pharmaceutical Industry , 1994 .
[124] S. Ikegawa. New gene associations in osteoarthritis: what do they provide, and where are we going? , 2007, Current opinion in rheumatology.
[125] Allen D. Roses,et al. Genome-based pharmacogenetics and the pharmaceutical industry , 2002, Nature Reviews Drug Discovery.
[126] Silke Schmidt,et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. , 2004, American journal of human genetics.
[127] A. J. Slater,et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. , 2008, Archives of neurology.
[128] A. Roses. Genetic testing for Alzheimer disease. Practical and ethical issues. , 1997, Archives of neurology.
[129] R. Weinshilboum,et al. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions , 2006, Oncogene.
[130] J. Woodcock,et al. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective , 2004, Nature Reviews Drug Discovery.
[131] Thomas Lengauer,et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.
[132] Philip Rosenstiel,et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci , 2007, Proceedings of the National Academy of Sciences.
[133] M. Relling,et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. , 2001, Cancer research.
[134] M. Sawicki,et al. Human Genome Project. , 1993, American journal of surgery.
[135] J. Galsworthy. A commentary , 1908 .
[136] J. Florez. The new type 2 diabetes gene TCF7L2 , 2007, Current opinion in clinical nutrition and metabolic care.
[137] AD Roses. Stimulation of Cholecystokinin‐A Receptors With Gl181771X: A Failed Clinical Trial That Did Not Test the Pharmacogenetic Hypothesis for Reduction of Food Intake , 2009, Clinical pharmacology and therapeutics.
[138] Norman A. Eisenberg,et al. A Regulatory Perspective on Model Validation , 1995 .
[139] Sonja W. Scholz,et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.
[140] M. McCarthy,et al. Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes , 2007, Science.
[141] P. Hamet,et al. Current status of genome-wide scanning for hypertension , 2007, Current opinion in cardiology.
[142] Ellen M Wijsman,et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. , 2007, Genomics.